Lite Strategy

Lite Strategy Graham Number

The Graham Number of Lite Strategy (LITS) as of Nov 20, 2026 is 7.34 USD. In the previous year, Graham Number was 6.71 USD — a change of 9.37% (higher).

Graham Number

7.34USD

YoY

9.37%

Last updated:

Graham Number of Lite Strategy is 2024 7.34 USD. Graham Number of Lite Strategy was 2023 6.71 USD. It decreases by 9.37% higher compared to the previous year.

The Lite Strategy Graham Number history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Graham Number
Date
Graham Number
Jan 1, 2017
6.71 USD
Jan 1, 2024
7.34 USD
The Lite Strategy Graham Number history
YEARGraham NumberYoY
7.34USD+9.37%
6.71USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Graham Number of Lite Strategy is 7.34 USD in 2024.

On Eulerpool you can find the complete historical development of Graham Number Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Lite Strategy

All Key Metrics — Lite Strategy